Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK/PD of Insulin Icodec in T2D
NCT04582435Phase 1Completed
- Sponsor
- Novo Nordisk
- Start
- Oct 2020
- Primary completion
- Apr 2022
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of insulin icodec in type 2 diabetes mellitus (T2DM), sponsored by Novo Nordisk. Primary endpoint: Area under the serum insulin icodec concentration-time curve during one dosing interval at steady state at Day 50. Started Oct 2020; status: completed.
02
Drugs
insulin icodec
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT04582435.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04582435.